Based on the Cidara Therapeutics Inc stock forecast from 7 analysts, the average analyst target price for Cidara Therapeutics Inc is USD 34.69 over the next 12 months. Cidara Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Cidara Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, Cidara Therapeutics Inc’s stock price was USD 19.18. Cidara Therapeutics Inc’s stock price has changed by +9.79% over the past week, -13.02% over the past month and +31.37% over the last year.
No recent analyst target price found for Cidara Therapeutics Inc
No recent average analyst rating found for Cidara Therapeutics Inc
Company Overview Cidara Therapeutics Inc
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California. Read Less
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and ...Read More
Frequently Asked Questions About Cidara Therapeutics Inc (CDTX) Stock
Based on ratings from 7 analysts Cidara Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 8 buy, sell and hold ratings.
Unfortunately we do not have enough data on CDTX's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for CDTX is USD 34.69 over the next 12 months. The maximum analyst target price is USD 46 while the minimum anlayst target price is USD 24.
Unfortunately we do not have enough data on CDTX's stock to indicate if its overvalued.
The last closing price of CDTX's stock was USD 19.18.
The most recent market capitalization for CDTX is USD 0.25B.
Based on targets from 7 analysts, the average taret price for CDTX is projected at USD 34.69 over the next 12 months.
This means that CDTX's stock price may go up by +80.86% over the next 12 months.
We can't find any ETFs which contains Cidara Therapeutics Inc's stock.
As per our most recent records Cidara Therapeutics Inc has 38 Employees.
Cidara Therapeutics Inc's registered address is 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121.
You can get more information about it from Cidara Therapeutics Inc's website at https://www.cidara.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Cidara Therapeutics Inc (CDTX) Stock
Based on ratings from 7 analysts Cidara Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 8 buy, sell and hold ratings.
Unfortunately we do not have enough data on CDTX's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for CDTX is USD 34.69 over the next 12 months. The maximum analyst target price is USD 46 while the minimum anlayst target price is USD 24.
Unfortunately we do not have enough data on CDTX's stock to indicate if its overvalued.
The last closing price of CDTX's stock was USD 19.18.
The most recent market capitalization for CDTX is USD 0.25B.
Based on targets from 7 analysts, the average taret price for CDTX is projected at USD 34.69 over the next 12 months.
This means that CDTX's stock price may go up by +80.86% over the next 12 months.
We can't find any ETFs which contains Cidara Therapeutics Inc's stock.
As per our most recent records Cidara Therapeutics Inc has 38 Employees.
Cidara Therapeutics Inc's registered address is 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121.
You can get more information about it from Cidara Therapeutics Inc's website at https://www.cidara.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CDTX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
